An observational study in Malignant Primary Pelvic Neoplasm, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Pelvic Neoplasms with a site in United States — 5 open to participants now, 9 under way, 2 of them phase 3. Pelvic Neoplasms · United States.
Among the 28 studies in Pelvic Neoplasms with a site in United States, this one is one of 2 that started in 2013, is one of 8 observational ones, and was the 20th registered.
82 studies on the registry are indexed under Pelvic Neoplasms; 28 are open to participants now.
Browse Pelvic Neoplasms studies →5 of the 28 studies in Pelvic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 6 mo–17 yrs
University of California, San Diego · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Pelvic Neoplasms studies recruiting now, 16 (70%) set no upper age limit and 3 (13%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 167 across 31 observational studies indexed under Pelvic Neoplasms.
Median enrollment 38 across the 20 interventional studies, 87 across the 8 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 28 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 3 studies filed under Pelvic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Pelvic Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06915727Phase 3Mayo ClinicAn Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors | 2027-05-01 |
| NCT05134142M.D. Anderson Cancer CenterQuality of Life and Function of Patients With Pelvic Tumors After Undergoing Hemipelvectomy | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Pelvic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to determine the functional outcomes of patients who underwent internal hemipelvectomy with or without reconstruction or external hemipelvectomy for pelvic tumors. Learning about the outcomes of these patients may help researchers determine the long-term effects of different types of hemipelvectomy procedures and may help improve quality of life.
PRIMARY OBJECTIVE:
I. To determine functions of patients who underwent internal hemipelvectomy with or without reconstruction or have had an external hemipelvectomy.
SECONDARY OBJECTIVES:
I. To determine factors that influence the functional outcomes of these patients following surgery.
II. Assess sexual and urinary function in patients who have undergone internal or external hemipelvectomy.
III. Determine whether type of surgery influences long-term sexual and urinary function.
OUTLINE:
Patients undergo physical performance assessments and complete quality of life assessments and questionnaires pre-hemipelvectomy, at 6 weeks post-hemipelvectomy, and then every 3 months up to 12 months and yearly thereafter for 10 years. Patients who are 1 year out from surgery complete pain-related questionnaires once. Patients who have already undergone hemipelvectomy prior to enrollment undergo medical record review.
Patients within the institution who have undergone or will undergo a hemipelvectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- None
Patients undergo physical performance assessments and complete quality of life assessments and questionnaires pre-hemipelvectomy, at 6 weeks post-hemipelvectomy, and then every 3 months up to 12 months and yearly thereafter for 10 years. Patients who are 1 year out from surgery complete pain-related questionnaires once. Patients who have already undergone hemipelvectomy prior to enrollment undergo medical record review.
Other: Electronic Health Record Review · Other: Physical Performance Testing · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Undergo medical record review
Undergo physical performance testing
Also known as: Physical Fitness Testing, Physical Function Testing
Complete assessments
Also known as: Quality of Life Assessment
Complete questionnaire
Functions of patients who underwent internal hemipelvectomy with or without reconstruction or have had an external hemipelvectomy
All continuous variables including the scoring systems will be described as mean with standard deviation or median with range. Frequencies and percentages will be obtained for all categorical variables. Pediatric participants' data measures will be collected and analyzed separately from the adult populations.
Time frame: Through study completion, average of 1 year
Started Mar 2013 (actual). Primary completion is estimated for Apr 2027, 169 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.